Northwestern Mutual Wealth Management
LVTX

Northwestern Mutual Wealth Management’s LAVA Therapeutics LVTX Stock Holding History

Northwestern Mutual Wealth Management’s Portfolio LVTX Stock Details LVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-20
Closed -$19 – 3827
2024
Q4 		$19 Buy
+20
New +$31 ﹤0.01% 3545

Other funds holding LVTX

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
BC
Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return
PFA
Pathway Financial Advisors South Burlington, Vermont $857M AUM 17.21% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Northwestern Mutual Wealth Management's LVTX Position: Q1 2025 in Review

Northwestern Mutual Wealth Management sold out of LAVA Therapeutics (LVTX) in Q1 2025, closing a stake of 20 shares — an estimated $19 sold.

Northwestern Mutual Wealth Management first reported a position in LVTX in Q4 2024 and held it in 1 quarter. The position peaked at $19 in Q4 2024. 20 funds tracked by Wall St. Rank hold LVTX as of Q1 2025.

  • Northwestern Mutual Wealth Management reported no remaining LAVA Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Northwestern Mutual Wealth Management sold 20 LAVA Therapeutics shares in Q1 2025, an estimated $19.
  • Northwestern Mutual Wealth Management first reported a position in LAVA Therapeutics in Q4 2024 and held it in 1 quarter.
  • Northwestern Mutual Wealth Management's LAVA Therapeutics position peaked at $19 in Q4 2024.
  • 20 funds tracked by Wall St. Rank held LAVA Therapeutics as of Q1 2025.

Based on Northwestern Mutual Wealth Management's 13F filing for Q1 2025, filed 14 May 2025.